CAS: 5957-80-2; (4Ar,9S,10As)-5,6-Dihydroxy-7-Isopropyl-1,1-Dimethyl-2,3,4,9,10,10A-Hexahydro-1H-9,4A-(Epoxymethano)Phenanthren-12-One

该化合物是一种自然形成的化合物,被归类为酚光双叶,主要在草药玫瑰(Rosmarinus officinalis)和Lamiacee家族的其他成员中发现.它以其抗氧化剂,抗炎和潜在的抗癌特性而著称,因为它对食品科学和药理都有兴趣.卡诺索尔展示了一个复杂的结构,由多个环和功能组组成,有助于其生物活动.该化合物溶解于有机溶剂,但水溶解性有限.其稳定性可能受到光和温度等环境因素的影响,这些因素可能影响其在不同应用中的功效.卡诺索尔已经研究其调制各种信号路径的能力,包括涉及氧化性压力和炎症的路径,表明它可能具有治疗用途.此外,由于它的抗微生物素特性,它经常被探讨在食品保护中的作用.

结构式图片

欧盟法规

C&L通报

上下游产品

CAS号3650-09-7 鼠尾草酸 | CAS号80225-53-2 迷迭香酚

合成工艺路线路线简述

    鼠尾草酸置于silver(L) Oxide体系中,用 二氯甲烷 作为反应溶剂,化学反应 1.5H,以67%的收率获得产物鼠尾草苦内脂
    参考文献:迷迭香中的鼠尾草酸和鼠尾草酚(抗氧化剂)由沙瓦拉(sawara)的主要成分哌啶酸合成.
    标题:迷迭香中的鼠尾草酸和鼠尾草酚(抗氧化剂)由沙瓦拉(sawara)的主要成分哌啶酸合成.
    摘要:鼠尾草酸(2)是迷迭香(rosmarinus Officinalis)中的一种主要抗氧化剂,它是由sawara(chamaecyparis Pisifera)的主要成分pisiferic Acid(1)合成的,其中苯酚使用间氯过氧化苯甲酸酯进行邻位氧化. Mcbpo),氯乙酰基间氯过氧化苯甲酰(camcbpo)或2-碘氧基苯甲酸(ibx).鼠尾草酚(3)是迷迭香中的另一种抗氧化剂,是由鼠尾草酸通过氧化银氧化而合成的.据报道,其对痤疮丙酸杆菌(atcc 6919)(最小抑菌浓度(mic)杯/毫升)和金黄色葡萄球菌me / Gm / Tc耐药(atcc 33592)(mic杯/毫升)的肌酸和鼠尾草酚均具有有效的抗菌活性.
    DOI:10.1248/cpb.58.27

    海关参考信息

    专利信息


    专利号:US-6391344-B2
    优先权日:1999-12-02
    标题:Method of promoting synthesis of nerve growth factor
    发明人:KOSAKA KUNIO; MIYAZAKI TOSHITSUGU; ITO HISATOMI
    权利人:NAGASE & CO LTD
    摘要:A method of promoting the synthesis of nerve growth factor comprising administering an effective amount of rosemary and/or sage extracts or carnosic acid and/or carnosol as an effective ingredient to a subject requiring such promotion. The present method can safely and efficiently promote the production of NGF in the living body, without being accompanied by a side effect such as a loss of a quantitative balance of hormones in the living body.

    专利号:WO-2017046598-A1
    优先权日:2015-09-16
    标题:Treatment of acute inflammatory disorders
    发明人:CRISANTI ANDREA; CANAVESE MIRIAM
    权利人:CRISANTI ANDREA; IMP INNOVATIONS LTD
    摘要:The present invention relates to a VEGF receptor agonist for use in the treatment of an acute inflammatory disorder associated with the overproduction of pro-inflammatory cytokine, administered with an agent that induces the synthesis of Nrf2. The invention also relates to pharmaceutical combinations comprising a VEGF receptor agonist and an agent that induces the synthesis of Nrf2, and kits comprising these agents. The described uses, combinations and methods may prevent or reduce the dis-regulated activation of an inflammatory response and reduce endothelial damage.

    专利号:US-2014357576-A1
    优先权日:2013-05-31
    标题:Methods for enhancement of muscle protein synthesis
    发明人:BREUILLE DENIS; STELLINGWERFF TRENT; MOORE DANIEL RYAN; OFFORD CAVIN ELIZABETH ANN; PHILLIPS STUART MARTIN
    权利人:NESTEC SA
    摘要:The present disclosure provides methods for enhancing muscle protein synthesis in an individual in need of same. Specifically, the present disclosure provides methods for enhancing muscle protein synthesis by enhancing myofibrillar muscle protein synthesis. The method includes administering to the individual a mixed macronutrient composition having (i) an amount of whey protein that is not capable of enhancing myofibrillar protein synthesis when ingested by itself and (ii) free leucine. The composition comprises at least about 5.0 g total leucine per dose.

    专利号:US-11273138-B2
    优先权日:2017-11-02
    标 题 :Use of amino acid supplementation for improved muscle protein synthesis
    发明人:WOLFE ROBERT R; FERRANDO ARNY
    权利人:BIOVENTURES LLC
    摘要:The present invention encompasses an amino acid composition for stimulating muscle protein synthesis. Further, the present disclosure relates generally to the use of an anabolic amino acid composition for the stimulation of muscle protein synthesis. In particular, disclosed are compositions and methods of using the same for the prevention and/or treatment of a loss of any one of muscle mass, muscle strength, muscle function, and physical function, or any combination thereof, in a mammal, especially an adult mammal. Also provided are kits comprising a composition for the stimulation of muscle protein synthesis and, in certain embodiments, instructions for administration.

    专利号:WO-2015040533-A1
    优先权日:2013-09-19
    标题:Methods for enhancing muscle protein synthesis during energy deficit
    发明人:BAILEY DAVID MARK; ZALTAS ERIC SCOTT; STELLINGWERFF TRENT; MOORE DANIEL RYAN; HAWLEY JOHN ALAN; BURKE LOUISE MARY
    权利人:PREMIER NUTRITION CORP
    摘要:The present disclosure provides methods for enhancing muscle protein synthesis in an individual in need of same. Specifically, the present disclosure provides methods for enhancing muscle protein synthesis during periods of negative energy balance, or energy deficit. The methods include administering to an individual suffering from energy deficit a composition comprising protein in an amount from about 15 g to about 30 g during a time period selected from the group consisting of during exercise, post-exercise, and combinations thereof. The methods also include administering to an individual suffering from energy deficit a composition comprising protein during a time period selected from the group consisting of during exercise, post-exercise, and combinations thereof, wherein the protein is administered in a dose that is higher than doses typically recommended for individuals experiencing energy balance.

    专利号:US-2014294788-A1
    优先权日:2013-03-26
    标 题 :Methods for enhancing muscle protein synthesis following concurrent training
    发明人:BAILEY DAVID MARK; ZALTAS ERIC SCOTT; MOORE DANIEL RYAN; STELLINGWERFF TRENT
    权利人:NESTEC SA
    摘要:The present disclosure provides methods for enhancing muscle protein synthesis following physical exertion. In a general embodiment, a method for enhancing muscle protein synthesis following physical exertion is provided and includes administering to an individual a composition comprising from about 15 to about 35 g protein immediately following concurrent training. Programs for enhancing muscle adaptation resulting from concurrent training are also provided. The programs include providing a composition comprising from about 15 to about 35 g protein; and providing guidelines for consumption including a recommendation of the amount of the composition to consume immediately following concurrent training.
    成都草源康生物科技有限公司
    ⚠️ 未注册 · 未认证企业
    ⚠️ 该商家尚未完成注册及企业认证,请用户仔细辨别,谨慎交易。
    数据来源于公开网络搜索,平台未作核实,请自行辨别。
    🏢敬请 企业认领
    🏬开设公司展台
    📢获取免费会员权益
    🎖️点亮专属注册企业标签
    📇展现公司完整信息 样本查看立即注册认领 →
    网址: http://www.caoyuankang.cn
    电话: 13438890071👤
    📞成都草源康生物科技有限公司 ⚠️参考联系方式

    销售电话:13438890071
    邮箱:3003796343@qq.com
    🆔 联系时候可告知是从"百琢研"平台获取的信息.
    ⚠️ 声明: 该企业未认证、未认领,请自行辨别信息的真实性和可靠性。咨询或交易时请注意风险评估与信息核实,百琢研不参与任何交易。企业认领注册入口→

    ⚠️ 未注册 · 未认证企业
    注册入口 备注: 📌 数据来源说明:本展台内容基于各搜索引擎等公开数据整理,仅作展示用途。请用户自行辨别 ✉️ 若企业需抹除展台内容或有异议, 请通过页面底部联系方式告知我们,我们会尽快处理。
    第 1 / 1 页
    现货

    供应商参考报价(招募中)

    品牌试剂参考报价(招募中)

    📌 第三方产品分析报告

    ✅ COA系统入驻 | 共享模式

    主要参考文献


    1: Li L, Pan Z, Ning D, Fu Y. Rosmanol and Carnosol Synergistically Alleviate Rheumatoid Arthritis through Inhibiting TLR4/NF-κB/MAPK Pathway. Molecules. 2021 Dec 23;27(1):78. doi: 10.3390/molecules27010078.
    2: Lu S, Li Y, Shen Q, Zhang W, Gu X, Ma M, Li Y, Zhang L, Liu X, Zhang X. Carnosol and its analogues attenuate muscle atrophy and fat lipolysis induced by cancer cachexia. J Cachexia Sarcopenia Muscle. 2021 Jun;12(3):779-795. doi: 10.1002/jcsm.12710. Epub 2021 May 5.
    3: O'Neill EJ, Hartogh DJD, Azizi K, Tsiani E. Anticancer Properties of Carnosol: A Summary of in Vitro and In Vivo Evidence. Antioxidants (Basel). 2020 Oct 8;9(10):961. doi: 10.3390/antiox9100961.

    合成参考文献


    摘要:Dembitsky, V. M.; Vil’, V. A., Science of Synthesis Knowledge Updates, (2019) 3, 345.
    摘要:Huang MT et al; Cancer Res 54 (3): 701-8 (1994)
    摘要:
    参考文献:10.1080/01635581.2015.1082110
    摘要:González-Vallinas M, Reglero G, Ramírez de Molina A. Rosemary (Rosmarinus officinalis L.) Extract as a Potential Complementary Agent in Anticancer Therapy. Nutrition and Cancer. 2015 Oct 09;67(8):1223–31. doi: 10.1080/01635581.2015.1082110.
    参考文献:10.3390/ijms19051321
    摘要:Vlavcheski F, Baron D, Vlachogiannis IA, MacPherson REK, Tsiani E. Carnosol Increases Skeletal Muscle Cell Glucose Uptake via AMPK-Dependent GLUT4 Glucose Transporter Translocation. Int J Mol Sci. 2018 Apr 29;19(5).
    📝 需求与反馈
    尽可能描述清楚需求与问题信息
    ×

    通知